TTI-101 targets STAT3/c-Myc signaling pathway to suppress cervical cancer progression: an integrated experimental and

Yi Li1, Yuyan Dong2

  • 1Department of Gynaecology, Shandong Provincial Third Hospital, Shandong University, No.11 Wuyingshan Middle Road, Tianqiao District, Jinan, 250031, Shandong, People's Republic of China.

PubMed
Abstract

Insights

TTI-101, a STAT3 inhibitor, shows promise in treating cervical cancer by halting cell growth and inducing apoptosis. This novel therapeutic agent effectively reduced tumor growth in preclinical models without significant side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cervical cancer (CC) presents a significant global health challenge, necessitating innovative therapeutic approaches.
  • The Signal Transducer and Activator of Transcription 3 (STAT3) pathway is recognized for its role in cancer progression and represents a potential therapeutic target.
  • This study investigates the potential of TTI-101, a small molecule inhibitor of STAT3, as a therapeutic agent for cervical cancer.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of TTI-101 in cervical cancer models.
  • To elucidate the underlying molecular mechanisms of TTI-101's action in cervical cancer cells.
  • To assess the safety and antitumor effects of TTI-101 in vivo.

Main Methods:

  • In silico studies including molecular docking and dynamics simulations to analyze STAT3-TTI-101 interactions.
  • In vitro assays: cell viability, wound healing, colony formation, flow cytometry, and gene expression analysis.
  • In vivo assessment using xenograft models to evaluate antitumor efficacy.

Main Results:

  • TTI-101 demonstrated stable binding to STAT3 and effectively inhibited cervical cancer cell viability, migration, and colony formation.
  • TTI-101 induced apoptosis and cell cycle arrest at the G2/M phase, with altered expression of key apoptosis and cell cycle regulatory proteins (Bax, Bcl-2, Caspase-3, CDK1, Cyclin B1).
  • In vivo studies showed significant inhibition of tumor growth by TTI-101 without adverse effects on body weight.

Conclusions:

  • TTI-101 exhibits significant anticancer effects in cervical cancer by targeting the STAT3/c-Myc pathway, inducing apoptosis, and causing cell cycle arrest.
  • These findings highlight TTI-101 as a promising therapeutic candidate for cervical cancer treatment.
  • Further clinical investigations are warranted to confirm the therapeutic potential of TTI-101.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.7K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K